Over the past few years, radiopharmaceuticals have been slowly becoming one of the most prominent modalities in oncology.

Alpha emitters, beta emitters, theranostic pairs.

But Auger emitters?

Almost nobody talks about those.

There’s a reason — auger electrons travel nanometers. Why is this a big deal?

Basically, it means they’re only lethal if you can get them inside the cell nucleus, right next to the DNA. Miss by even a fraction and they do nothing. It’s one of the hardest delivery problems in nuclear medicine.

Cellectar Biosciences thinks their phospholipid ether (PLE) platform solves it. PLEs exploit altered lipid metabolism in cancer cells, getting selectively absorbed and retained inside tumor cells rather than healthy tissue. The company reports a 20-fold increase in delivery to cancerous cells compared to unconjugated compounds, validated across 60+ preclinical cancer models.

Their newest program, CLR 125, is an iodine-125 Auger emitter conjugated to this PLE backbone. The target: refractory triple-negative breast cancer.

First patient was enrolled in a Phase 1b trial running at Mayo Clinic.

TNBC is a worthy test case. Here’s why.

It’s one of the most aggressive breast cancers and has the fewest targeted options. There’s no HER2 to target, no hormone receptors to block. Most patients cycle through chemo until they run out of lines.

A radioconjugate that selectively gets inside TNBC cells and delivers DNA-damaging radiation at nuclear range is a fundamentally different approach. Preclinical data showed selective tumor uptake and antitumor activity without systemic toxicity.

Cellectar isn’t new to radiopharmaceuticals. Their lead asset, iopofosine I-131, uses the same PLE platform with a beta-emitting payload. It hit 83.6% overall response rate in relapsed/refractory Waldenström’s macroglobulinemia, earning FDA Breakthrough Therapy Designation, six Orphan Drug Designations, and four Rare Pediatric Drug Designations. That program validated the delivery tech.

CLR 125 asks the next question: can the same platform work in solid tumors with an Auger payload?

They’ve also got an actinium-225 alpha emitter in development for pancreatic cancer. Three radioisotope classes (beta, Auger, alpha), one delivery platform. If the PLE backbone keeps performing across all three, that’s a platform story, not a single-asset story.

Phase 1b primary objective: recommended Phase 2 dose.

Trial is at Mayo Clinic. Keep your eye on this new modality.